ly3437943 retatrutide triple agonist glp-1 gip glucagon Research Peptide Australia | GLP-1/GIP/Glucagon Retatrutide (LY3437943), a Novel GIP/GLP-1/Glucagon
Description
The highest dose studied in Phase 2, producing up to 24.2% average weight loss at 48 weeks
The prescribed dose is the prescribed dose regardless of timing
P =0.95) (Fig
Im glad to see more recognition of adiposity-based conditions sharing treatment strategies
The researchers evaluate the treatments safety, determine a safe dosage range, and identify side effects
The evidence below is per-compound, plus the CagriSema (cagrilintide + semaglutide) Phase 3 data as the closest analog
